181
Participants
Start Date
December 6, 2019
Primary Completion Date
October 17, 2023
Study Completion Date
December 31, 2026
Gilteritinib
"Induction: 120 mg orally daily x 14 days starting on day 8~Consolidation: 120 mg orally daily x 14 days starting on day 8 of each cycle (up to 4 cycles)"
Midostaurin
"Induction: 50 mg orally twice daily x 14 days beginning on day 8~Consolidation: 50 mg orally twice daily x 14 days beginning on day 8 of each cycle (up to 4 cycles)"
Daunorubicin
"First Induction: Daunorubicin 90 mg/m²/day IV Days 1,2,3~Second Induction, if needed: Daunorubicin 45 mg/m²/day IV Days 1,2,3"
Cytarabine
"Induction: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Second Induction, if needed: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Consolidation: Cytarabine 3 g/m² (recommend 1.5 g/m² for age ≥ 55 or patients with decreased creatinine clearance) every 12 hours IV Days 1,3,5 or Days 1-3 for 6 doses for up to 4 cycles"
Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York
Weill Cornell Medicine New York Presbyterian Hospital, New York
Northwell Health, Lake Success
SUNY Upstate Medical University, Syracuse
University of Rochester Medical Center, Rochester
University of Pittsburgh Medical Center, Pittsburgh
Penn State Milton S. Hershey Medical Center, Hershey
Geisinger Medical Center, Danville
University of Pennsylvania, Philadelphia
Thomas Jefferson University, Philadelphia
Johns Hopkins University, Baltimore
West Virginia University, Morgantown
East Carolina University, Greenville
Augusta University Medical Center, Augusta
Mayo Clinic- Jacksonville, FL, Jacksonville
Vanderbilt University, Nashville
University of Kentucky Markey Cancer Center, Lexington
University Hospitals Cleveland Medical Center, Cleveland
University of Cincinnati Medical Center, Cincinnati
Franciscan Health Indianapolis, Indianapolis
St. Joseph's Mercy Hospital, Ann Arbor
UW Cancer Center at ProHealth Care, Waukesha
Medical College of Wisconsin, Milwaukee
University of Wisconsin Clinical Science Center, Madison
Marshfield Medical Center, Marshfield
Mayo Clinic- Rochester, MN, Rochester
University of Chicago Medical Center, Chicago
Northwestern University Feinberg School of Medicine, Chicago
University of Nebraska Medical Center, Omaha
Ochsner Clinic Foundation, New Orleans
University of Oklahoma Stephenson Cancer Center, Oklahoma City
LDS Hospital, Salt Lake City
HonorHealth Research Institute, Scottsdale
UCLA, Los Angeles
UC Irvine Health, Orange
University of California, San Francisco-Fresno (University Oncology Associates), Clovis
Kaiser Permanente Santa Clara, Santa Clara
Kaiser Permanente Oakland, Oakland
Kaiser Permanente Roseville, Roseville
MultiCare, Spokane
Tufts Medical Center, Boston
Massachusetts General Hospital, Boston
Atlantic Health Systems/Morristown Medical Center, Morristown
Collaborators (1)
Astellas Pharma Inc
INDUSTRY
PrECOG, LLC.
OTHER